boehringer glp 1 advances #first #triple #agonist #bi3034701 #obesity #pipeline #glp #gip #npy2 #glucagon #glp #boehringeringelheim #obesity #glp1 #gip #npy2 #cardiometabolic #phase2 #clinicaltrials #drugdevelopment… GLP-1 Agonists: A Comprehensive Overview

Morbidity improvements are generally lower than mortality improvements due to a higher proportion of morbidity incidence (in a critical illness product) being caused by cancers (where the relative risks of incidence by BMI are lower), compared to mortality, with a higher proportion of deaths caused by CVD (where the relative risks by BMI are higher)

Phase 2 data published in the New England Journal of Medicine (2023) demonstrated substantial weight loss in adults with obesity, but the medicine is not yet approved for clinical use in the UK

Lembas has just closed an oversubscribed pre-seed funding round of $3.6m (3m) led by Flora Ventures, which it will use to scale-up production and commercialise its bioactive, coined GLP-1 Edge

Foeniculum vulgare ) Organic Lemon Peel ( Rich in bioflavonoids to help combat oxidative stress